ORCID Profile
0000-0002-2681-2846
Current Organisations
Grande Ospedale Metropolitano Niguarda
,
Università degli Studi di Milano
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487226.V1
Abstract: Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487229.V1
Abstract: Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: Elsevier BV
Date: 05-2012
Abstract: To perform a subset analysis of patients with partially platinum-sensitive recurrent ovarian cancer (ROC) who received either CD [carboplatin-pegylated liposomal doxorubicin (PLD)] or CP (carboplatin-paclitaxel) in the CALYPSO trial. CALYPSO, an international phase III, non-inferiority trial, enrolled women with ROC that relapsed >6 months following first- or second-line therapy. Patients were randomized to CD or CP. Patients with a treatment-free interval of >6 and ≤ 12 months were evaluated for progression-free survival (PFS), the primary end point of CALYPSO trial, and safety. A total of 344 partially platinum-sensitive patients were included (N = 161, CD and N = 183, CP). The hazard ratio for PFS was 0.73 (95% confidence interval: 0.58-0.90 P = 0.004 for superiority) in favor of CD. Median PFS times were 9.4 months (CD) and 8.8 months (CP). Toxicities more common with CP versus CD included grade 3/4 neutropenia (50% versus 39% P = 0.015), grade 2 alopecia (86% versus 9% P < 0.001), neuropathy and hypersensitivity reactions. Hand-foot syndrome was more common with CD however, grade 3/4 reactions were low (one patient in each arm). Carboplatin-PLD has a more favorable risk-benefit profile than CP in patients with partially platinum-sensitive ROC and should be considered an effective treatment option for these patients.
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487232.V1
Abstract: Supplementary Data from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487223.V1
Abstract: Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487208.V1
Abstract: Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487208
Abstract: Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487229
Abstract: Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: American Association for Cancer Research (AACR)
Date: 10-02-2022
DOI: 10.1158/1078-0432.CCR-21-3597
Abstract: Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and previously induced deep [objective response rate (ORR) 57.4%] and durable [median duration of response (DoR) 10.4 months] responses in adults with NTRK fusion-positive solid tumors from three phase I/II trials. This article expands prior reports with additional patients and longer follow-up. Patients with locally advanced/metastatic NTRK fusion-positive solid tumors and ≥12 months' follow-up were included. Primary endpoints were ORR and DoR by blinded independent central review (BICR) secondary endpoints included progression-free survival (PFS), intracranial efficacy, and safety. The safety-evaluable populations included all patients who had received ≥1 entrectinib dose. At clinical cut-off (August 31, 2020), the efficacy-evaluable population comprised 121 adults with 14 tumor types and ≥30 histologies. Median follow-up was 25.8 months 61.2% of patients had a complete (n = 19) or partial response (n = 55). Median DoR was 20.0 months [95% confidence interval (CI), 13.0–38.2] median PFS was 13.8 months (95% CI, 10.1–19.9). In 11 patients with BICR-assessed measurable central nervous system (CNS) disease, intracranial ORR was 63.6% (95% CI, 30.8–89.1) and median intracranial DoR was 22.1 (95% CI, 7.4–not estimable) months. The safety profile of entrectinib in adults and pediatric patients was aligned with previous reports. Most treatment-related adverse events (TRAEs) were grade 1/2 and manageable/reversible with dose modifications. TRAE-related discontinuations occurred in 8.3% of patients. With additional clinical experience, entrectinib continues to demonstrate durable systemic and intracranial responses and can address the unmet need of a CNS-active treatment in patients with NTRK fusion-positive solid tumors.
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487217
Abstract: Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487226
Abstract: Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487217.V1
Abstract: Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487214
Abstract: Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.C.6532467.V1
Abstract: AbstractPurpose: Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and previously induced deep [objective response rate (ORR) 57.4%] and durable [median duration of response (DoR) 10.4 months] responses in adults with i NTRK /i fusion-positive solid tumors from three phase I/II trials. This article expands prior reports with additional patients and longer follow-up. Patients and Methods: Patients with locally advanced/metastatic i NTRK /i fusion-positive solid tumors and ≥12 months' follow-up were included. Primary endpoints were ORR and DoR by blinded independent central review (BICR) secondary endpoints included progression-free survival (PFS), intracranial efficacy, and safety. The safety-evaluable populations included all patients who had received ≥1 entrectinib dose. Results: At clinical cut-off (August 31, 2020), the efficacy-evaluable population comprised 121 adults with 14 tumor types and ≥30 histologies. Median follow-up was 25.8 months 61.2% of patients had a complete ( i n /i = 19) or partial response ( i n /i = 55). Median DoR was 20.0 months [95% confidence interval (CI), 13.0–38.2] median PFS was 13.8 months (95% CI, 10.1–19.9). In 11 patients with BICR-assessed measurable central nervous system (CNS) disease, intracranial ORR was 63.6% (95% CI, 30.8–89.1) and median intracranial DoR was 22.1 (95% CI, 7.4–not estimable) months. The safety profile of entrectinib in adults and pediatric patients was aligned with previous reports. Most treatment-related adverse events (TRAEs) were grade 1/2 and manageable/reversible with dose modifications. TRAE-related discontinuations occurred in 8.3% of patients. Conclusions: With additional clinical experience, entrectinib continues to demonstrate durable systemic and intracranial responses and can address the unmet need of a CNS-active treatment in patients with i NTRK /i fusion-positive solid tumors. /
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.C.6532467
Abstract: AbstractPurpose: Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and previously induced deep [objective response rate (ORR) 57.4%] and durable [median duration of response (DoR) 10.4 months] responses in adults with i NTRK /i fusion-positive solid tumors from three phase I/II trials. This article expands prior reports with additional patients and longer follow-up. Patients and Methods: Patients with locally advanced/metastatic i NTRK /i fusion-positive solid tumors and ≥12 months' follow-up were included. Primary endpoints were ORR and DoR by blinded independent central review (BICR) secondary endpoints included progression-free survival (PFS), intracranial efficacy, and safety. The safety-evaluable populations included all patients who had received ≥1 entrectinib dose. Results: At clinical cut-off (August 31, 2020), the efficacy-evaluable population comprised 121 adults with 14 tumor types and ≥30 histologies. Median follow-up was 25.8 months 61.2% of patients had a complete ( i n /i = 19) or partial response ( i n /i = 55). Median DoR was 20.0 months [95% confidence interval (CI), 13.0–38.2] median PFS was 13.8 months (95% CI, 10.1–19.9). In 11 patients with BICR-assessed measurable central nervous system (CNS) disease, intracranial ORR was 63.6% (95% CI, 30.8–89.1) and median intracranial DoR was 22.1 (95% CI, 7.4–not estimable) months. The safety profile of entrectinib in adults and pediatric patients was aligned with previous reports. Most treatment-related adverse events (TRAEs) were grade 1/2 and manageable/reversible with dose modifications. TRAE-related discontinuations occurred in 8.3% of patients. Conclusions: With additional clinical experience, entrectinib continues to demonstrate durable systemic and intracranial responses and can address the unmet need of a CNS-active treatment in patients with i NTRK /i fusion-positive solid tumors. /
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487223
Abstract: Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487211
Abstract: Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487211.V1
Abstract: Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487232
Abstract: Supplementary Data from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487214.V1
Abstract: Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487220
Abstract: Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: American Association for Cancer Research (AACR)
Date: 31-03-2023
DOI: 10.1158/1078-0432.22487220.V1
Abstract: Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With i NTRK /i Fusion-Positive Solid Tumors
Publisher: Elsevier BV
Date: 2003
No related grants have been discovered for SALVATORE SIENA.